NASD · Healthcare · Biotechnology · United Kingdom
Mereo Biopharma Group Plc ADR is a micro cap company (market value under $300 million) in the Biotechnology industry.
Mereo Biopharma Group Plc ADR is a biopharmaceutical company developing therapeutics for rare diseases. Its late-stage candidates include setrusumab for osteogenesis imperfecta and alvelestat for severe alpha-1 antitrypsin deficiency-associated lung disease, along with an early-stage program, vantictumab, for autosomal dominant osteopetrosis. The company also has non-core programs available for partnership.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Mereo Biopharma Group Plc ADR stock.
Not valued: We cannot value this company yet.
134 more in this industry show a wider margin of safety.
We do not publish a verdict on MREO yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.
We do not publish one (as of the 2026-10-30 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.